Evidence review · standard

tesamorelin

bundle · json · system map · manifest

Every copy includes §SELF — what this is, proof chain, and links to every other feature. No context required.

§SELF — this page explains the system
## §SELF — miscsubjects (paste without context)

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `human_page` — **Human article page**
Rendered article with claims, sources, copy widgets, ask prompts.
- **article slug:** `tesamorelin`
- **contains:** rendered article, copy widgets, claims, sources, ask prompts
- **how to use:** Use Copy for LLM or Copy system map — both paste without context.
- **read:** https://miscsubjects.com/a/tesamorelin

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/tesamorelin/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **bundle** — Paste-ready package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/tesamorelin/bundle?format=markdown
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/tesamorelin/prompts
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/tesamorelin/topology

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

*Not medical advice. Tier-honest. Cite claim/source ids.*

Regeneration vs degeneration — where this fits

The body is always doing two things at once: breaking down (degeneration) and building back (regeneration). A condition persists when breakdown outruns repair. Most drugs used for symptoms suppress a signal (pain, acid, anxiety, inflammation) without fixing the tissue that caused the signal. Peptides in this ledger are studied for repair pathways: new blood vessels, repair-cell migration, nerve regrowth, gut lining, neural connections. This article maps one compound through that frame — what it is, how it is proposed to work, what evidence exists, and what people report.

What it is

2026 meta-analysis of RCTs concluding tesamorelin benefits body composition and hepatic fat in HIV lipodystrophy with favorable safety. 2025 clinical study on tesamorelin effects on neurocognitive impairment in HIV patients with abdominal obesity.

Why it would work (logic chain)

  1. IF 2026 meta-analysis of RCTs concluding tesamorelin benefits body composition and hepatic fat in HIV lipodystrophy with favorable safety. THEN that is one proposed link in a repair/regeneration pathway (not yet proven end-to-end in humans unless a human claim says so).
  2. IF 2025 clinical study on tesamorelin effects on neurocognitive impairment in HIV patients with abdominal obesity. THEN that is one proposed link in a repair/regeneration pathway (not yet proven end-to-end in humans unless a human claim says so).
  3. IF 2024 subanalysis of RCT showing tesamorelin reduces visceral fat, hepatic fat, and improves fat distribution in HIV patients on integrase inhibitors, well-tolerated. THEN that is one proposed link in a repair/regeneration pathway (not yet proven end-to-end in humans unless a human claim says so).
  4. IF Ongoing 2026 Phase 2 trial evaluating tesamorelin plus exercise in HIV patients for physical function and muscle health. THEN that is one proposed link in a repair/regeneration pathway (not yet proven end-to-end in humans unless a human claim says so).
  5. IF New 2026 Phase II trial protocol for tesamorelin in MASLD/NAFLD. THEN that is one proposed link in a repair/regeneration pathway (not yet proven end-to-end in humans unless a human claim says so).

How many people take it

There is no reliable global count of how many people take this compound. That number is not in this ledger.

What we can count from this ledger:

  • 0 anecdote source(s) (posts, threads, comments)
  • 0 anecdote-tier claim(s) derived from them

Logic: Without catalogued Reddit/X posts, this article cannot answer how many people take it — only what studies exist.

Evidence inventory

This is a count of what is in this ledger — not a claim about all research worldwide.

  • Scientific sources catalogued (PubMed, trials, reviews): 5
  • Claims tagged human evidence: 5
  • Claims tagged preclinical (animal/lab): 0
  • Claims tagged anecdotal: 0
  • Reddit posts catalogued: 0
  • X posts catalogued: 0
  • Other anecdote sources (YouTube, Instagram, etc.): 0
  • Total sources in chain: 5

Logic: No social posts catalogued yet — we cannot report what people are saying on Reddit or X from this ledger.

Quantified confidence (this ledger): 0.73 / 1.00 — moderate — human claims present in ledger

Formula: human claims×0.12 + preclinical×0.04 + anecdote×0.015 + studies (capped). This is not clinical certainty — it measures how much graded evidence is catalogued here.

What scientists say

Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials (source s1)

2026 meta-analysis of RCTs concluding tesamorelin benefits body composition and hepatic fat in HIV lipodystrophy with favorable safety.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity (source s2)

2025 clinical study on tesamorelin effects on neurocognitive impairment in HIV patients with abdominal obesity.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

Tesamorelin as an Adjunct to Exercise for Improving Physical Function and Muscle Health in Adults With HIV (TRIUMPH Trial) (source s3)

Ongoing 2026 Phase 2 trial evaluating tesamorelin plus exercise in HIV patients for physical function and muscle health.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors (source s4)

2024 subanalysis of RCT showing tesamorelin reduces visceral fat, hepatic fat, and improves fat distribution in HIV patients on integrase inhibitors, well-tolerated.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study) (source s5)

New 2026 Phase II trial protocol for tesamorelin in MASLD/NAFLD.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

---

Not medical advice. Counts and quotes are from this article's hash-chained ledger. Anecdote = real reports, not proof. Animal studies ≠ human proof.

Tesamorelin · peptide map

Evidence map

Hover a node — its path lights up. Click to open the article.

Full map →
JumpBenzo WithdrawalBenzodiazepinesBrain FogCarpal Tunnel
Evidence · 5 sources · swipe →chain 853bbca21979 · verify chain · provenance
1 / 5
Evidence ledger 5 · tier-ranked · API
human
2026 meta-analysis of RCTs concluding tesamorelin benefits body composition and hepatic fat in HIV lipodystrophy with favorable safety.
sources: s1
human
2025 clinical study on tesamorelin effects on neurocognitive impairment in HIV patients with abdominal obesity.
sources: s2
human
2024 subanalysis of RCT showing tesamorelin reduces visceral fat, hepatic fat, and improves fat distribution in HIV patients on integrase inhibitors, well-tolerated.
sources: s4
humanlow confidence
Ongoing 2026 Phase 2 trial evaluating tesamorelin plus exercise in HIV patients for physical function and muscle health.
sources: s3
humanlow confidence
New 2026 Phase II trial protocol for tesamorelin in MASLD/NAFLD.
sources: s5
Model swipes · 3 from 1 model · swipe →verify
1 / 3
grok-4.3writer
draft2026-06-29 17:02
tesamorelin
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: tesamorelin
it output
2 source(s) added
24b3f450bec2390a
grok-4.3source_hunt
sources2026-06-29 17:02
3 source(s) added · 3 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: tesamorelin
it output
2 source(s) added
2f7e2e52bf644143
grok-4.3source_hunt
sources2026-06-29 17:02
2 source(s) added · 2 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: tesamorelin
it output
2 source(s) added
44e64c3ee65f1c89

Related research

Tesamorelin · peptide map

Open evidence map →
Benzo Withdrawaltesamorelin-benzo-withdrawalBenzodiazepinestesamorelin-benzodiazepinesBrain Fogtesamorelin-brain-fogCarpal Tunneltesamorelin-carpal-tunnelChemotesamorelin-chemoChemo Neuropathytesamorelin-chemo-neuropathyCognitiontesamorelin-cognitionCorticosteroidstesamorelin-corticosteroidsDiabetic Neuropathytesamorelin-diabetic-neuropathyFrozen Shouldertesamorelin-frozen-shoulder
Ask this article · 7 suggested prompts
topology · JSON · question graph

Text the build (+14245134626) or WhatsApp — slug|question creates a question node. Paste evidence with ingest slug|q:NODE_ID|your paste.

What does the ledger say about this (human tier): "2026 meta-analysis of RCTs concluding tesamorelin benefits body composition and hepatic fat in HIV lipodystrophy with favorable safety."?
ask tesamorelin claim c1 · paste includes §SELF
What does the ledger say about this (human tier): "2025 clinical study on tesamorelin effects on neurocognitive impairment in HIV patients with abdominal obesity."?
ask tesamorelin claim c2 · paste includes §SELF
What does the ledger say about this (human tier): "2024 subanalysis of RCT showing tesamorelin reduces visceral fat, hepatic fat, and improves fat distribution in HIV patients on integrase in…"?
ask tesamorelin claim c4 · paste includes §SELF
What does the ledger say about this (human tier): "Ongoing 2026 Phase 2 trial evaluating tesamorelin plus exercise in HIV patients for physical function and muscle health."?
ask tesamorelin claim c3 · paste includes §SELF
What does the ledger say about this (human tier): "New 2026 Phase II trial protocol for tesamorelin in MASLD/NAFLD."?
ask tesamorelin claim c5 · paste includes §SELF
For my medical situation, what can you answer from your catalogue about tesamorelin — and what would you need me to tell you first?
ask tesamorelin condition gaps · paste includes §SELF
What good and bad outcomes are documented for tesamorelin (studies vs anecdotes)?
ask tesamorelin good bad experiences · paste includes §SELF
Add your experience or question
Think this article is wrong?
Call bullshit on CharlieOS →